BriaCell presses up new company with a couple of preclinical cancer meds

BriaCell Therapeutics is plucking a couple of preclinical mixtapes and seeing how they sound in a new studio, forming a fresh spinout company to develop the early meds.

The new company, which has been dubbed SpinCo in the release, will have a preclinical PKCδ inhibitor and immunotherapy, BriaCell announced Thursday morning. The new entity will be majority-owned and controlled by BriaCell, and existing BriaCell shareholders will be able to buy in. Once the transaction is complete, BriaCell shareholders will receive one share of the slimmed-down BriaCell and one share of SpinCo.